Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Interferon alfa-2a

Interferon alfacon-1 (Inferax ), interferon alfa-2b (IntronA ), and interferon alfa-2a (Roferon -A) are applied in the treatment of chronic hepatitis B and C and some malignancies, especially hairy cell leukemia. IFN-a proteins induce the expression of antiviral, antiproliferative and immunomodulatory genes. [Pg.411]

Carreno V, MarceUin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jimenez FJ, Quiroga JA (1999) Retreatment of chrome hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. Hepatology 30 277-282... [Pg.231]

Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D et al (1994) Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330 88-94... [Pg.233]

Interferon alfa is an antiviral agent that is effective in suppressing hepatitis B viral replication. Interferon alfa-2b and pegylated interferon alfa-2a are the only interferon therapies approved for the treatment of chronic hepatitis B. [Pg.353]

The subcutaneous dose of interferon alfa-2b (Intron A) in patients who are HBsAg-positive is either 5 million units daily (better tolerated) or 10 million units three times weekly. The dose for HBsAg-negative patients is 5 to 6 million units three times weekly. The approved dose for pegylated interferon alfa-2a (Pegasys) for chronic hepatitis B is 180 meg subcutaneously once weekly. Interferon doses may need to be adjusted in patients with renal impairment. [Pg.354]

Interferon alfa-2a (Roferon A), interferon alfa-2b (Intron-A), and interferon alfacon-1 (Infergen) are approved for chronic hepatitis C. However, they are not prescribed alone because only 12% to 16% of patients achieve a sustained virologic response (SVR). Adding ribavirin, a synthetic guanosine analogue that inhibits viral polymerase, increases the SVR rate to 35% to 45%. [Pg.356]

Interferon alfa-2a Interferon alfa-2b 18 million IU 18 million IU 209.58 218.04 Roferon-A Intron-A ... [Pg.185]

Immunogenicity Nine percent of patients treated with peginterferon alfa-2a with or without ribavirin tablets developed binding antibodies to interferon alfa-2a, as assessed by an ELISA assay. The clinical and pathological significance of the appearance of serum neutralizing antibodies is unknown. [Pg.1991]

Oseltamivir (Tamiflu) Palivizumab (Synagis) Peg Interferon Alfa-2a (Pegsys)... [Pg.37]

Hairy cell leukemia Interferon alfa-2a-. Subcutaneous, IM Initially, 3 million units/day for 16-24 wk. Maintenance 3 million units 3 times/wk. Do not use 36-million-unit vial. Interferon alfa-2b Subcutaneous, IM 2 million units/m 3 timesAvk. If severe adverse reactions occur, modify dose or temporarily discontinue. [Pg.632]

Chronic myelocytic leukemia (CML) Interferon alfa-2a-. Subcutaneous, IM 9 million units daily. [Pg.632]

Melanoma Interferon alfa-2a-. Subcutaneous, IM 12 million units/m 3 times/wk for 3 mo. Interferon alfa-2b-. IV Initially, 20 million units/m 5 times/wk for 4 wk. Maintenance 10 million units IM/SCfor48 wk. [Pg.632]

Interferon alfa-2a Treatment of active, chronic hepatitis, bladder or renal carcinoma, malignant melanoma, multiple myeloma, mycosis fungoides, non-Hodgkin s lymphoma... [Pg.632]

Interferon alfa-2a-. Partial alopecia, rash, dry throat or skin, pruritus, flatulence, constipation, hypertension, palpitations, sinusitis... [Pg.633]

Interferon alfa-2a-. Hot flashes, hypermotility, Raynaud s syndrome, bronchospasm, earache, ecchymosis... [Pg.633]

Arrhythmias, stroke, transient ischemic attacks, congestive heart failure (CHF), pulmonary edema, and myocardial infarction (Ml) occur rarely with interferon alfa-2a,... [Pg.633]

Weekly administration of peginterferon alfa-2a equivalent to 3 times weekly administration of interferon alfa-2a for hepatitis C... [Pg.946]

Hepatitis B therapy interferon alfa-2a interferon alfa-2b... [Pg.625]

Ezekowitz, R.A., J.B. Mulliken, and J. Eolkman, Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med, 1992.326(22) 1456-63. [Pg.178]

Fried, M.W., M.L. Shiffman, R.K. Reddy, et al., Pegylated interferon alfa-2a in combination with ribavirin efficacy and safety results... [Pg.185]

Recommended dosage and monitoring requirements The recommended dose of Roferon-A for chronic hepatitis C is 3 million international units (MIU) three times a week for 12 months. The recommended dose for CML is 9 MIU daily optimal duration of therapy has not been determined. The recommended dose for hairy cell leukemia is 3 MIU daily for 16 to 24 weeks. The recommended dose for AIDS-related Kaposi s sarcoma is 36 MIU daily for 10 to 12 weeks. There are five types of interferon alfa currently available in the United States interferon alfa-2a, peginterferon alfa-2a, interferon alfa-2b, interferon alfacon-1, and interferon alfa n3. Doses are not consistent for these preparations. [Pg.190]

Clinical pharmacology The mechanism by which interferon alfa-2a recombinant, or any other interferon, exerts antitumor or antiviral activity is not clearly... [Pg.190]

Pharmacokinetics A mean elimination half-life of approximately 5 hours has been reported after intravenous doses of Roferon-A. Pharmacokinetic parameters are similar in healthy subjects and cancer patients after intramuscular doses. Dose-proportionate increases in serum levels occur with doses up to 198 MIU. The bioavailability of interferon alfa-2a after intramuscular administration is 80% to 83%, and its volume of distribution is 0.223 to 0.748 liter/kg. The total body clearance of interferon alfa-2a has been reported to range from 2.14 to 3.62ml/min per kg. [Pg.191]

Disposition Like other alpha interferons, interferon alfa-2a undergoes extensive proteolytic degradation in the kidney (during tubular reabsorption) hepatic metabolism is minimal. [Pg.191]

F. Role in therapy According to Micromedex, Roferon-A is recommended as the drug of choice in renal carcinoma and the chronic phase of chronic myelogenous leukemia. The role of Gleevec (Ima-tinib) in CML is yet to be determined, but it may replace the use of interferon alfa-2a. Roferon-A is an alternative (for unrespon-sive/intolerant patients) to current regimens of choice in hairy-cell leukemia, multiple myeloma, metastatic melanoma, and AIDS-related Kaposi s sarcoma. Other alpha interferons appear to have similar efficacy and can be used in lieu of Roferon-A in some instances. In particular, interferon alfa-2b (Intron) can be considered to have the same role as interferon alfa-2a in chronic hepatitis C, Kaposi s sarcoma, and hairy-cell leukemia. [Pg.191]

H. Other considerations Interferon alfa-2a has been designated an orphan drug product for the treatment of chronic myelogenous leukemia, AIDS-related Kaposi s sarcoma, renal cell carcinoma, metastatic malignant melanoma, and esophageal and colorectal cancer. [Pg.192]

F. Role in therapy According to Micromedex, current agents of choice in the treatment of chronic hepatitis C are interferon alfa-2a, alfa-2b,alfacon-l, peginterferon alfa-2b, or alfa-2b plus ribavirin. Efficacy of these interferons is similar, although response rates have been higher with the addition of oral ribavirin. In a... [Pg.206]

See other pages where Interferon alfa-2a is mentioned: [Pg.240]    [Pg.356]    [Pg.1267]    [Pg.213]    [Pg.1990]    [Pg.249]    [Pg.249]    [Pg.639]    [Pg.631]    [Pg.632]    [Pg.632]    [Pg.633]    [Pg.614]    [Pg.178]    [Pg.189]    [Pg.190]    [Pg.190]    [Pg.191]    [Pg.193]   
See also in sourсe #XX -- [ Pg.59 , Pg.60 , Pg.61 , Pg.62 , Pg.63 , Pg.64 , Pg.65 , Pg.66 ]



SEARCH



Interferon alfa

Peg interferon alfa-2a

© 2024 chempedia.info